NASDAQ:KOD Kodiak Sciences Q4 2025 Earnings Report $32.35 -0.87 (-2.62%) Closing price 04:00 PM EasternExtended Trading$40.55 +8.20 (+25.34%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kodiak Sciences EPS ResultsActual EPS-$1.04Consensus EPS -$1.02Beat/MissMissed by -$0.02One Year Ago EPSN/AKodiak Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKodiak Sciences Announcement DetailsQuarterQ4 2025Date3/31/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsKodiak Sciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Kodiak Sciences Earnings HeadlinesKodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration9 minutes ago | prnewswire.comUpcoming DAYBREAK Trial Results in Wet AMD Could Be A Game Changer For Kodiak Sciences (KOD)September 24 at 11:26 AM | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 25 at 1:00 AM | InvestorPlace (Ad)Kodiak Sciences (KOD) Stock Looks Overvalued After Its 15x RunSeptember 24 at 11:26 AM | finance.yahoo.comThe Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteSeptember 23 at 11:30 PM | finance.yahoo.comAnalysts Set Kodiak Sciences Inc. (NASDAQ:KOD) Target Price at $48.14September 23 at 3:59 AM | americanbankingnews.comSee More Kodiak Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email. Email Address About Kodiak SciencesKodiak Sciences (NASDAQ:KOD) (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration. Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration. Kodiak has also pursued KSI-501, a bispecific antibody biopolymer conjugate designed to target both VEGF and interleukin-6 pathways in retinal disease. Founded in 2009 and based in Palo Alto, California, Kodiak Sciences has focused primarily on research and clinical development rather than commercialized products. The company was founded and led by Victor H. Perlroth, who has served as its chief executive officer and a member of its board. Its clinical development activities have primarily addressed global ophthalmology markets through clinical trials and collaborations.View Kodiak Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
